Approach may offer new way to reverse disability in multiple sclerosis patients
A pair of topical medicines already alleviating skin conditions may prove to have another, even more compelling use: instructing stem cells in the brain to reverse damage caused by multiple sclerosis.
Led by researchers at Case Western Reserve University, a multi-institutional team used a new discovery approach to identify drugs that could activate mouse and human brain stem cells in the laboratory. The two most potent drugs—one that currently treats athlete’s foot, and the other, eczema—were capable of stimulating the regeneration of damaged brain cells and reversing paralysis when administered systemically to animal models of multiple sclerosis. The results were published online (dx.doi.org/10.1038/nature14335) Monday, April 20, in the scientific journalNature.
“We know that there are stem cells throughout the adult nervous system that are capable of repairing the damage caused by multiple sclerosis, but until now, we had no way to direct them to act,” said Paul Tesar, the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics, and associate professor in the Department of Genetics & Genome Sciences at the Case Western Reserve School of Medicine. “Our approach was to find drugs that could catalyze the body’s own stem cells to replace the cells lost in multiple sclerosis.”
The findings mark the most promising developments to date in efforts to help the millions of people around the world who suffer from multiple sclerosis. The disease is the most common chronic neurological disorder among young adults, and results from aberrant immune cells destroying the protective coating, called myelin, around nerve cells in the brain and spinal cord.
Without myelin, neural signals cannot be transmitted properly along nerves; over time, a patient’s ability to walk, hold a cup or even see is inexorably eroded. Current multiple sclerosis therapies aim to slow further myelin destruction by the immune system, but the Case Western Reserve team used a new approach to create new myelin within the nervous system. Their work offers great promise of developing therapies that reverse disabilities caused by multiple sclerosis or similar neurological disorders.
“To replace damaged cells, much of the stem cell field has focused on direct transplantation of stem cell-derived tissues for regenerative medicine, and that approach is likely to provide enormous benefit down the road,” said Tesar, also a New York Stem Cell Foundation Robertson Investigator and member of the National Center for Regenerative Medicine. “But here we asked if we could find a faster and less invasive approach by using drugs to activate native stem cells already in the adult nervous system and direct them to form new myelin. Our ultimate goal was to enhance the body’s ability to repair itself.”
Tesar emphasized that much work remains before multiple sclerosis patients might benefit from the promising approach. Scientists still must find ways to transform the topical medications for internal use and determine their long-term efficacy and potential side effects. That said, using existing, federally approved drugs enhances the likelihood that the compounds can be made safe for human use.
Read more: Drugs stimulate body’s stem cells to replace the brain cells lost in multiple sclerosis
The Latest on: Multiple Sclerosis
[google_news title=”” keyword=”Multiple Sclerosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Multiple Sclerosis
- National multiple sclerosis society lauds Lewiston doctoron June 1, 2023 at 11:29 am
Dr. Alison Daigle, a provider of care for people living with multiple sclerosis in Lewiston, has been recognized as a Neurologic Care Partner through the National Multiple Sclerosis Society’s Partners ...
- Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trialon June 1, 2023 at 9:50 am
Sanofi's anti-CD40L antibody frexalimab demonstrated reduced disease activity in a Phase II trial of patients with relapsing multiple sclerosis (RMS).
- Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goalon May 31, 2023 at 9:02 am
Sanofi SNY announced positive data from a phase II study, which showed that its novel investigational anti-CD40L antibody, frexalimab, significantly reduced disease activity in patients with relapsing ...
- Sanofi: Frexalimab Phase 2 Trial Meets Primary Goal In Relapsing Multiple Sclerosison May 30, 2023 at 10:27 pm
French drug major Sanofi S.A. (SNYNF, SNY) announced Wednesday positive Phase 2 data of novel investigational anti-CD40L antibody ...
- Sanofi announces positive data for frexalimab product to treat multiple sclerosison May 30, 2023 at 9:10 pm
French healthcare company Sanofi announced on Wednesday positive data for its frexalimab product aimed at treating multiple sclerosis, and that the firm plans to initiate pivotal trials in multiple ...
- Multiple Sclerosis Research Newson May 30, 2023 at 5:00 pm
Mar. 16, 2023 — Criteria used by neurologists to assess for multiple sclerosis (MS) in adults may fail to identify the illness in children with imaging suspicious for the disease, an oversight ...
- Multiple Sclerosis hides in plain sight: 'Early treatment is associated with better outcomes'on May 30, 2023 at 9:22 am
Multiple Sclerosis (MS) impacts about 1 in every 400 people, according to the Multiple Sclerosis Clinic at Riverside Regional Medical Center.
- What Is World Multiple Sclerosis Day?on May 30, 2023 at 7:54 am
While some know all about multiple sclerosis day, others may not be aware of the meaning behind the day. Here's what you need to know regarding MS Day.
- Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communicationon May 30, 2023 at 1:30 am
Day, we speak to Dr. Cameron McAlpine about his latest research that sought to understand better the proteins and signals that act as messengers between brain and immune cells in MS.
- Volunteer with personal connection gives back to Rocky Mountain Multiple Sclerosis Centeron May 29, 2023 at 5:06 am
Debby Laurita has a deep connection with the Multiple Sclerosis Center and the enrichment program thanks to her daughter. After her daughter passed away, Debby said she felt called to give back.
via Bing News